Baricitinib (Olumiant; Eli Lilly) demonstrated meaningful efficacy and a favorable safety profile in adults with severe alopecia areata in a real-world prospective study, with more than half of patients achieving substantial hair regrowth within…
Baricitinib Shows Real-World Effectiveness in Severe Alopecia Areata Hair Loss
